| Autoantibodies against type I IFNs in patients with life-threatening COVID-19 P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ... Science 370 (6515), eabd4585, 2020 | 2463 | 2020 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review R Castagnoli, M Votto, A Licari, I Brambilla, R Bruno, S Perlini, F Rovida, ... JAMA pediatrics 174 (9), 882-889, 2020 | 1356 | 2020 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 441 | 2021 |
| An immune-based biomarker signature is associated with mortality in COVID-19 patients MS Abers, OM Delmonte, EE Ricotta, J Fintzi, DL Fink, AAA de Jesus, ... JCI insight 6 (1), 2021 | 325 | 2021 |
| Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19 K Sacco, R Castagnoli, S Vakkilainen, C Liu, OM Delmonte, C Oguz, ... Nature medicine 28 (5), 1050-1062, 2022 | 182 | 2022 |
| Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives R Castagnoli, OM Delmonte, E Calzoni, LD Notarangelo Frontiers in pediatrics 7, 295, 2019 | 180 | 2019 |
| Asthma endotyping and biomarkers in childhood asthma A Licari, R Castagnoli, I Brambilla, A Marseglia, MA Tosca, GL Marseglia, ... Pediatric allergy, immunology, and pulmonology 31 (2), 44-55, 2018 | 168 | 2018 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 128 | 2022 |
| The nose and the lung: united airway disease? A Licari, R Castagnoli, CF Denicolò, L Rossini, A Marseglia, GL Marseglia Frontiers in Pediatrics 5, 44, 2017 | 125 | 2017 |
| Omalizumab in children A Licari, A Marseglia, S Caimmi, R Castagnoli, T Foiadelli, S Barberi, ... Pediatric Drugs 16, 491-502, 2014 | 115 | 2014 |
| HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur … P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ... Science 370 (6515), eabd4585, 2020 | 91 | 2020 |
| Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases … F Cardinale, G Ciprandi, S Barberi, R Bernardini, C Caffarelli, M Calvani, ... Italian journal of pediatrics 46, 1-14, 2020 | 88 | 2020 |
| Inborn errors of immunity with immune dysregulation: from bench to bedside OM Delmonte, R Castagnoli, E Calzoni, LD Notarangelo Frontiers in pediatrics 7, 353, 2019 | 86 | 2019 |
| From IgE to clinical trials of allergic rhinitis G Ciprandi, GL Marseglia, R Castagnoli, C Valsecchi, C Tagliacarne, ... Expert Review of Clinical Immunology 11 (12), 1321-1333, 2015 | 85 | 2015 |
| The discovery and development of omalizumab for the treatment of asthma A Licari, GL Marseglia, R Castagnoli, A Marseglia, G Ciprandi Expert opinion on drug discovery 10 (9), 1033-1042, 2015 | 84 | 2015 |
| Neutralizing type‐I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID‐19 MS Abers, LB Rosen, OM Delmonte, E Shaw, P Bastard, L Imberti, ... Immunology and cell biology 99 (9), 917-921, 2021 | 82 | 2021 |
| Allergy and asthma in children and adolescents during the COVID outbreak: what we know and how we could prevent allergy and asthma flares A Licari, M Votto, I Brambilla, R Castagnoli, E Piccotti, R Olcese, ... Allergy 75 (9), 2402, 2020 | 78 | 2020 |
| Omalizumab in children with severe allergic asthma: the Italian real-life experience A Licari, R Castagnoli, C Denicolò, L Rossini, M Seminara, L Sacchi, ... Current Respiratory Medicine Reviews 13 (1), 36-42, 2017 | 71 | 2017 |
| Dupilumab to treat type 2 inflammatory diseases in children and adolescents A Licari, R Castagnoli, A Marseglia, F Olivero, M Votto, G Ciprandi, ... Pediatric Drugs 22 (3), 295-310, 2020 | 68 | 2020 |
| Eosinophilic gastrointestinal diseases in children: a practical review A Licari, M Votto, E D'Auria, R Castagnoli, SME Caimmi, GL Marseglia Current pediatric reviews 16 (2), 106-114, 2020 | 64 | 2020 |
Amelia LicariUniversità degli Studi di PaviaEmail verificata su unipv.it
